AtriCure (ATRC) Stock Forecast & Price Target

AtriCure is attractive because its Q3 revenue of $154.5M rose 15.1% on a constant-currency basis, with especially strong U.S. momentum in Open Ablation, Appendage Management, and Pain Management, while gross margin expanded to 77.3% and adjusted EBITDA reached nearly $27M. The company’s raised 2026 guidance to $606M-$610M of sales and $91M-$94M of adjusted EBITDA suggests management is seeing durable demand and improving operating leverage, not just a one-quarter spike. Its outlook is further supported by long-run growth catalysts such as the BoxX-NoAF trial nearing full enrollment, the Jan. 1, 2027 STS quality metric, and a full-year adjusted EBITDA midpoint of $92.5M that reflects a tripling in three years.

AtriCure is facing a negative fundamental setup because the bear case assumes revenue growth slows to below 11% as Minimally Invasive Ablation, Appendage Management, and Pain Management sales underperform while profitability improves more slowly than expected. The risk profile is amplified by possible disappointing EPi-Sense/Convergent sales, weaker Open Ablation and AtriClip demand, and market share loss to Medtronic’s Penditure surgical LAA closure device, all of which would pressure core product momentum. With the downside scenario tied to roughly $42 per share on about 3.0x 2027E sales and weaker-than-expected margins, the outlook reflects both slower top-line expansion and constrained earnings leverage.